How does orlistat (Xenical) work for weight loss? Dosing and effects

How does orlistat work?

Orlistat reduces absorption of some dietary fat by blocking enzymes involved in fat digestion. It is used alongside dietary and activity changes. It does not suppress appetite or guarantee weight loss.

Acting mainly in the digestive tract does not mean it has a “clean” safety profile or no effects elsewhere. Nutrient absorption, other medicines and uncommon serious reactions still matter.

Xenical and Alli have different product instructions

EMA information describes prescription Xenical for adults with a BMI of at least 30, or at least 28 with associated risk factors. Its product information specifies a treatment review after 12 weeks and discontinuation if at least 5% of starting body weight has not been lost.

Alli is a lower-strength orlistat product with a separate indication for adults with BMI at least 28. Its information describes professional advice if weight loss has not occurred after 12 weeks and a maximum six-month course.

Do not apply Xenical's exact stopping rule or capsule strength to every orlistat product. Authorisation and non-prescription status in the EMA record do not prove local stock or access through a particular service.

Using a prescribed or pharmacy-supplied product

Follow the exact product's directions for meals, dose and duration. Avoid taking extra capsules to compensate for a high-fat meal or to accelerate weight loss.

The medicine is intended to accompany a nutritionally balanced, reduced-calorie plan. Ask a professional about fat distribution across meals, vitamin supplementation and the timing of other medicines. This guide does not provide a personal diet or dosing plan.

Side effects and important checks

Oily stools, urgency and gas with discharge are recognised effects. They can be more troublesome with higher-fat meals. These effects do not prove that treatment is producing a healthy or adequate weight-loss response.

Chronic malabsorption and cholestasis are important exclusions. Pregnancy, breastfeeding, kidney problems and a history of relevant illness need product-specific assessment. Product information also describes liver-injury reports and oxalate-related kidney concerns; low absorption is not proof that these risks are absent.

Tell a clinician or pharmacist about medicines such as ciclosporin, anticoagulants, levothyroxine and antiepileptics. The restrictions differ between products and combinations may require avoidance, dose separation or monitoring.

Seek prompt medical advice for jaundice, dark urine, significant abdominal pain or other serious new symptoms.

How much weight loss should you expect?

A fixed multiplier against GLP-1 medicines would require an appropriate direct comparison. This guide does not infer one from unrelated trials.

Instead, agree realistic goals, a review date, how response will be measured and what happens if treatment is unsuitable or ineffective. Trial averages cannot promise an individual's result.

Information and clinical decisions

This guide provides general information, not a diagnosis or personal treatment plan. Any clinical assessment and prescribing decision rests with an independent clinician. Prescrivia is a technology intermediary, not a medical provider or pharmacy; it does not prescribe, sell or dispense medicines. Assessment does not guarantee a prescription, medicine availability or a health outcome.

Further reading: treatment information.

Read about online consultations and their limits. Service information must not delay urgent local care.

Sources

1. EMA: Xenical — Prescription indication, mechanism and use alongside diet.
2. EMA: Xenical product information — Twelve-week 5% response rule, interactions, nutrient effects and liver/kidney safety information.
3. EMA: Alli — Separate BMI threshold, lower-strength product, non-prescription authorisation, review and maximum treatment duration.

See the current clinical, legal and language review statuses for this edition. Source checks are editorial work, not approval.